Wednesday, January 09, 2013

FDA reviewers: Diabetes drug may pose heart risk

Johnson & Johnson's experimental diabetes drug could bring minor heart risks because it raised cholesterol levels in patient testing, or so claim to federal drug reviewers.
According to documents released this week, FDA staffers read  studies that showed J&J's canagliflozin raised levels of LDL, or bad cholesterol. 
Several  studies did not find other serious problems, such as weakening of bones, damage to the liver or kidneys, or various cancers.